MT-1 10mg

MT-1 (afamelanotide) is a linear alpha-MSH analogue with preferential selectivity for MC1R, the melanocyte receptor that drives skin pigmentation. MT-2 (Melanotan II) is a cyclic analogue that is a non-selective melanocortin receptor agonist with significant activity at MC1R, MC3R, MC4R, and MC5R. The MC4R activity of MT-2 produces pro-erectile and appetite-suppressing effects that MT-1 largely lacks. For research specifically on melanocyte biology, photoprotection, or MC1R pharmacology, MT-1 is the more appropriate compound. For studying MC4R or mixed melanocortin receptor effects, MT-2 is used.

Erythropoietic protoporphyria (EPP) is a rare genetic disorder caused by deficient ferrochelatase activity, leading to accumulation of protoporphyrin IX in red blood cells and skin. When protoporphyrin IX absorbs UV light, it generates reactive oxygen species that cause intense burning pain and phototoxicity. Patients must avoid sunlight completely, severely limiting daily activities. MT-1 (afamelanotide) increases eumelanin in the skin through MC1R activation, which absorbs UV light before it reaches photosensitizing protoporphyrin molecules. This melanin shield extends the time EPP patients can tolerate sun exposure, providing meaningful quality-of-life improvement.

Yes, Melanotan I and afamelanotide refer to the same compound. Afamelanotide is the INN (International Nonproprietary Name) used in clinical and regulatory contexts, while "Melanotan I" or "MT-1" is the commonly used research name. The compound is the same linear alpha-MSH analogue regardless of the name used. The clinical product (Scenesse) delivers it as a subcutaneous bioresorbable implant; research applications typically use reconstituted solution for injection.